drugset / Trial / NCT00151619

Effects of Amlodipine in the Management of Chronic Heart Failure

NCT00151619

Phase 2 Terminated 7 enrolled Rennes University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Patients with congestive heart failure are usually treated with a combination of an ACE inhibitor (or an AT1 blocking agent), a diuretic and a beta-blocker. However, some patients remain symptomatic despite an optimal treatment with these drugs. In patients who also have coronary heart disease, nitrates or some calcium-channel blockers could help to relieve symptoms. Therefore, the aim of our study is to evaluate the additional benefit induced by a second generation calcium-channel blocker, amlodipine, in patients with chronic heart failure who remain symptomatic despite an optimal treatment.

Timeline

Start
1999-02-10
Primary completion
2001-09-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Amlodipine Other / unclassified 10 mg

Indications